Madrigal Pharmaceuticals, Inc. Forecast, price target & analysts
Madrigal Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Madrigal Pharmaceuticals, Inc. Classifications & Recommendation:
Madrigal Pharmaceuticals, Inc. Price Target
| Target Price | $411.31 |
| Price | $335.74 |
| Potential |
22.51%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Madrigal Pharmaceuticals, Inc. 2026 .
The average Madrigal Pharmaceuticals, Inc. target price is $411.31.
This is
22.51%
register free of charge
$544.00
62.03%
register free of charge
$239.00
28.81%
register free of charge
|
|
| A rating was issued by 17 analysts: 15 Analysts recommend Madrigal Pharmaceuticals, Inc. to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Madrigal Pharmaceuticals, Inc. stock has an average upside potential 2026 of
22.51%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 180.13 | 577.27 |
| 220.47% | ||
| EBITDA Margin | -275.79% | -74.79% |
| 72.88% | ||
| Net Margin | -267.47% | -48.70% |
| 81.79% |
16 Analysts have issued a sales forecast Madrigal Pharmaceuticals, Inc. 2025 . The average Madrigal Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Madrigal Pharmaceuticals, Inc. EBITDA forecast 2025. The average Madrigal Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Madrigal Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Madrigal Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -21.90 | -12.78 |
| 9.55% | 41.64% | |
| P/E | negative | |
| EV/Sales | 11.28 |
17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast for earnings per share. The average Madrigal Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Madrigal Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Madrigal Pharmaceuticals, Inc....
Current Madrigal Pharmaceuticals, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup | Locked ➜ Locked | Locked | Feb 27 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 27 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 14 2025 |
| JMP Securities | Locked ➜ Locked | Locked | Jan 10 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Nov 20 2024 |
| B. Riley Securities | Locked ➜ Locked | Locked | Nov 05 2024 |
| UBS | Locked ➜ Locked | Locked | Nov 01 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 14 2025 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Nov 20 2024 |
|
Locked
B. Riley Securities: Locked ➜ Locked
|
Nov 05 2024 |
|
Locked
UBS: Locked ➜ Locked
|
Nov 01 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
